DocDollars

Ibsa Pharma Inc.

NJ · United States · Reporting entity ID 100000226810

Total reported 2019–2025
$1.66M
#1,108 of 2,960 reporting companies — 0% of all reported industry payments
$1.42M in general payments across 57,241 records, plus $245K in research funding across 26 records.

How it breaks down

General payments $1,416,907
Research funding $244,541

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Ibsa Pharma Inc. reported $1.66M to US doctors and teaching hospitals from 2019 to 2025, ranking #1,108 of 2,960 reporting companies. 15% of that was research funding and 85% general payments such as consulting, speaking, food and travel. 57,241 general payment records and 26 research records were filed.

Common questions about Ibsa Pharma Inc.

How much has Ibsa Pharma Inc. paid US doctors?

Ibsa Pharma Inc. reported $1,661,448 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $1,416,907 in general payments, $244,541 in research funding.

How does Ibsa Pharma Inc. rank among drug and device companies?

It ranks #1,108 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Ibsa Pharma Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.